Clinical study of PhageBankTM for chronic infections following joint replacement
Latest Information Update: 10 Apr 2024
At a glance
- Drugs Bacteriophage therapeutics-BiomX (Primary)
- Indications Bacterial infections
- Focus Therapeutic Use
- 18 Mar 2024 According to a BiomX media release, Adaptive Phage Therapeutics has been acquired and merged into BiomX
- 10 Aug 2020 New trial record
- 05 Aug 2020 According to an Adaptive Phage Therapeutics, the company anticipates initiating the PJI trial at Mayo Clinic in the fall of 2020.If successful, the company anticipates potential commercial availability in 2023.